Welcome to our dedicated page for Rockwell Med SEC filings (Ticker: RMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rockwell Medical’s filings rarely stop at numbers—each 8-K can hint at FDA feedback, every 10-K buries pages of dialysis supply logistics, and Form 4 insider selling often precedes capital raises. Finding those signals is tough when disclosures stretch past 200 pages. That’s the problem investors face with Rockwell Medical’s complex renal-care narrative.
Stock Titan solves it. Our AI reads every Rockwell Medical annual report 10-K simplified, each Rockwell Medical quarterly earnings report 10-Q filing, and even the swift Rockwell Medical 8-K material events explained, then delivers clear summaries you can scan in minutes. Need to track Rockwell Medical insider trading Form 4 transactions? Receive Rockwell Medical Form 4 insider transactions real-time and view executive stock transactions Form 4 alongside plain-English context. Trying to compare margins quarter over quarter? Our AI maps segment data automatically, turning “other COGS” footnotes into usable charts.
Because dialysis economics hinge on concentrate pricing and Triferic adoption, you’ll discover exactly where management discloses reimbursement updates, patent expirations, and manufacturing capacity—all flagged inside the filing. Use cases include:
- Review Rockwell Medical proxy statement executive compensation before voting
- Monitor cash-burn trends with Rockwell Medical earnings report filing analysis
- Spot board purchases via Rockwell Medical insider trading Form 4 transactions alerts
Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 2,149,471 shares of Rockwell Medical common stock, representing 6.29% of the class. The reporting persons state they exercise shared voting and dispositive power over these shares through Armistice Capital's role as investment manager of the Armistice Capital Master Fund, the direct holder. The Master Fund is identified as the record owner but disclaims beneficial ownership due to the investment management agreement. No sole voting or dispositive power is reported.
The disclosure clarifies ownership structure and control relationships: Armistice Capital acts as adviser and Steven Boyd, as managing member, is identified as having shared beneficial influence over the reported position.
Rockwell Medical (RMTI) reported a sharp decline in sales following reduced volumes from its largest customer. Net sales were $16.1 million for the quarter (down 38% year-over-year) and $35.0 million for the six months (down 28%). Gross margin held near 16%, but the company recorded a net loss of $1.5 million for the quarter and $3.0 million year-to-date, driven largely by a $9.9 million quarterly reduction in DaVita purchases and a $14.6 million reduction for the six-month period.
Liquidity sources include $18.4 million of cash, cash equivalents and short-term investments, $21.1 million available under an ATM facility, and net working capital of $20.7 million; management believes these resources are sufficient for at least the next twelve months. The Company has an outstanding term loan with a net carrying amount of $8.6 million, current deferred consideration of $2.5 million, and completed remediation with its lender by submitting updated projections. The Company also disclosed a new multimillion-dollar supply agreement with IRC with three-year utilization commitments.
Rockwell Medical, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025, and attached that press release as Exhibit 99.1 to this Current Report on Form 8-K. The company explicitly states the information in Item 2.02 and Exhibit 99.1 is being furnished and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into Securities Act filings except by specific reference. Item 9.01 lists the furnished exhibits: Exhibit 99.1 (press release) and Exhibit 104 (Cover Page Interactive Data File in Inline XBRL). The report is signed on behalf of the registrant by Mark Strobeck, Chief Executive Officer.
FAQ
What is the current stock price of Rockwell Med (RMTI)?
What is the market cap of Rockwell Med (RMTI)?
